Is personalised immunotherapy for brain tumours available in Australia?

Personalised cancer vaccines and combined checkpoint inhibitor approaches for glioblastoma are investigational — they are not currently part of standard care and are not available outside of clinical trials. Several international trials are underway following the scientific momentum generated by cases like Professor Scolyer's. For Australians with a brain tumour diagnosis, the best source of information about current clinical trials is the Australian Cancer Trials website (australiancancertrials.gov.au). Any trial participation should be discussed with your treating oncologist.

Richard Scolyer's patient-zero experiment: what it changed for brain cancer

Q: What is glioblastoma and how is it usually treated in Australia?

Glioblastoma (grade 4 IDH-wildtype glioblastoma multiforme, GBM) is the most aggressive primary brain tumour in adults. Standard treatment is surgery to remove as much tumour as possible, followed by radiotherapy and the chemotherapy agent temozolomide — the Stupp protocol. Median survival on standard treatment is approximately 15 months. Long-term survival beyond two years occurs in fewer than 5% of patients. Glioblastoma's infiltrative growth pattern means complete surgical removal is impossible; tumour cells spread into surrounding brain tissue not visible on imaging. There is no cure with current standard-of-care treatment, and this is why the global immunotherapy research effort matters.

What just happened

AusDoc’s Paul Smith has examined the clinical and human legacy of Professor Richard Scolyer, who died in June 2026 of grade 4 IDH-wildtype glioblastoma — the most aggressive adult brain tumour — three years after his diagnosis. Scolyer was co-director of the Melanoma Institute Australia, one of the world’s leading immunotherapy research centres, and 2024 Australian of the Year alongside his research partner Professor Georgina Long.

When Scolyer was diagnosed in 2023, he was one of the world’s leading experts in personalised cancer immunotherapy. He had spent years understanding how the immune system could be trained to recognise and attack melanoma. Glioblastoma is a different disease entirely — a brain cancer rather than a skin cancer, with a very different biology and a much bleaker prognosis — but the underlying mechanism he had spent a career studying still applied.

He and his team designed an experimental protocol combining a personalised neoantigenic cancer vaccine — engineered against his tumour’s specific mutations — with checkpoint inhibitor immunotherapy. No human being had received this combination for glioblastoma in this form. He volunteered to be the first.

Dr Helen Wheeler, the oncologist who worked with his treatment team, later described the weight of that moment: “I didn’t know if his brain was going to blow up or not.”

Both-and

What the experiment was not

It is important to be clear about what Scolyer’s self-experimentation was not. It was not a cure. He died of glioblastoma three years after his diagnosis. The personalised immunotherapy protocol did not eliminate his tumour.

It is also not a template that can be immediately applied to patients with brain cancer. The protocol he received was designed and administered by a world-leading immunotherapy team with deep expertise in checkpoint inhibitors and personalised vaccine design — expertise built on decades of melanoma research. It was an N-of-1 experiment under exceptional conditions.

And it was not without risk. The honest acknowledgement from Dr Wheeler — that she did not know what would happen to his brain — reflects a genuine scientific uncertainty that had to be held alongside the decision to proceed. Experimental treatment always carries that weight, and this one more so than most.

What it actually changed

What Scolyer’s experiment did produce is data, and that data now exists. The case generated global scientific attention and reshaped the research conversation about what immunotherapy might offer for glioblastoma — a disease that has proved deeply resistant to every treatment advance that has transformed outcomes in other cancers over the past twenty years.

He survived three years. The median survival for grade 4 glioblastoma on standard treatment is approximately 15 months. Long-term survival beyond two years occurs in fewer than 5% of patients. Whether the immunotherapy protocol contributed meaningfully to his extended survival, and to what degree, is a question the scientific literature will continue to examine. But the data from his case is inside that literature now.

There is also a second thing his case changed: the public conversation about experimental consent. Scolyer was a scientist who understood exactly what he was agreeing to. He gave fully informed consent in the most literal possible sense — consent that integrated his own clinical expertise with his oncology team’s. That kind of consent is not available to most patients with a terminal cancer diagnosis, who are navigating an extraordinarily difficult situation without his level of scientific background.

His case raises a question that oncology ethics will sit with for some time: what does informed consent mean when the patient being asked is one of the leading experts on the treatment being offered?

What this means for patients with brain tumours now

For most Australians diagnosed with glioblastoma, the standard of care remains surgery, radiotherapy, and temozolomide. Personalised immunotherapy is not currently available outside of clinical trials.

What Scolyer’s case does offer is evidence that the immunotherapy approach is worth pursuing — that the immune system can be directed toward a glioblastoma, that the protocol can be tolerated, and that survival can exceed what standard treatment alone typically delivers. That is enough to justify accelerating the trial program, which is what his scientific legacy will continue to do.

My two cents

What Professor Scolyer did was not reckless. It was a considered scientific act under full consent, with clear awareness of the risks, performed by someone who had spent a career understanding exactly what he was asking his immune system to do.

The fact that it did not cure him is not a failure of the science. It is the nature of where glioblastoma research currently sits. The disease is extraordinarily difficult. The immunotherapy field is still building the foundational knowledge that might, eventually, change outcomes at scale.

He donated three years of his own biological experience — including the experience of dying — to that project. The scientific record is richer for it, and so is the conversation about what terminal cancer patients can access, and what they can consent to.

For anyone who has had a loved one diagnosed with glioblastoma and has felt the inadequacy of what standard treatment offers — this story is not a cure. But it is a direction, and directions matter when you are trying to find a way through.

Verdict: yes — Professor Scolyer’s patient-zero immunotherapy experiment generated real data for one of cancer medicine’s hardest problems and permanently changed the conversation about experimental treatment for glioblastoma.

Sources cited

Smith P. Glioblastoma and the legacy of Professor Richard Scolyer’s ‘patient zero’ immunotherapy experiment. AusDoc, 28 July 2026. https://www.ausdoc.com.au/news/glioblastoma-and-the-legacy-of-professor-richard-scolyers-patient-zero-immunotherapy-experiment/
Melanoma Institute Australia. https://www.melanoma.org.au/